Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBT Margin (2016 - 2025)

Ironwood Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 174.85% for Q4 2025.

  • For Q4 2025, EBT Margin fell 20135.0% year-over-year to 174.85%; the TTM value through Dec 2025 reached 4.7%, down 2326.0%, while the annual FY2025 figure was 54.42%, 3586.0% up from the prior year.
  • EBT Margin for Q4 2025 was 174.85% at Ironwood Pharmaceuticals, down from 55.69% in the prior quarter.
  • Across five years, EBT Margin topped out at 67.41% in Q4 2022 and bottomed at 1002.24% in Q2 2023.
  • The 5-year median for EBT Margin is 41.91% (2021), against an average of 36.45%.
  • The largest annual shift saw EBT Margin plummeted -105755bps in 2023 before it surged 102223bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 39.49% in 2021, then skyrocketed by 71bps to 67.41% in 2022, then plummeted by -348bps to 166.88% in 2023, then skyrocketed by 116bps to 26.5% in 2024, then plummeted by -760bps to 174.85% in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBT Margin are 174.85% (Q4 2025), 55.69% (Q3 2025), and 44.33% (Q2 2025).